Telix expands US footprint with $366m deal for RLS

Melbourne-based biotech Telix Pharmaceuticals (ASX: TLX) has expanded its North American manufacturing base through the acquisition of RLS (USA) Inc for up to US$250 million ($366.5 million).

The deal gives Telix access to 3http://www.businessnewsaustralia.com/1 licensed radiopharmacies operated…